Inhibikase Therapeutics, Inc. Common Stock IKT
$2.23
-3.26%
at last close
Financials (TTM)
- Revenue
- $3.72 million
- Net Income
- $-60,637,002
- Net Margin
- -1632.18%
- Return on Equity
- -39.55%
- Debt-to-Equity
- —
- P/E Ratio
- —
- Price / Book
- 2.09
- Price / Sales
- 86.39
Over the trailing twelve months, Inhibikase Therapeutics, Inc. Common Stock generated revenue of $3.72 million and net income of $-60,637,002, a net margin of -1632.18%.
At the last closing price of $2.23, IKT trades at 86.39 times sales, with a market capitalization of $320.93 million.
Key Stats
- Last Close
- $2.23
- Market Cap
- $320.93 million
- 52-Week Range
- $1.33 – $2.61
- Average Volume
- 490K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.